Migd-061 ⟶

| Model | Dosing Regimen | Endpoints & Results | |-------|----------------|---------------------| | | 30 mg/kg PO QD, 21 days | Tumor growth inhibition (TGI) = 62 % vs. vehicle; enhanced CD8⁺ T‑cell infiltration (↑ 2.3‑fold). | | Humanized NSG mouse xenograft (A549) + anti‑PD‑1 | MIGD‑061 15 mg/kg PO QD + pembrolizumab 10 mg/kg IP Q3D | Combination TGI = 84 % (vs. 48 % for pembrolizumab alone). | | SOD1‑G93A ALS mouse model | 10 mg/kg PO BID, started at P60 | Delayed onset of motor decline by 12 days; ↑ survival median + 8 days (p = 0.03). | | Dengue virus (DENV‑2) in AG129 mice | 25 mg/kg PO BID, 5 days post‑infection | Viral load in serum ↓ 1.7 log₁₀; survival 70 % vs. 30 % in control. |

– This review synthesises all publicly‑available information on MIGD‑061 (also referenced as “MIGD‑061”) up to April 2026, focusing on its chemical profile, mechanism of action, pre‑clinical pharmacology, early clinical data, safety signals, and market outlook. Where data are proprietary or not disclosed, the gaps are highlighted and speculative commentary is clearly flagged. migd-061

Users searching for this code often encounter it on specialized databases such as the JAV Database or JAVLibrary , which provide metadata including actress profiles, user ratings, and official distribution links. | Model | Dosing Regimen | Endpoints &

, a unit of measurement for water flow or capacity. If this is a reference to a specific technical manual or industrial model (such as a pump or water treatment component), it may be an internal company identifier. If you intended to "create text" using a specific software or tool that uses this ID, please provide a bit more context about the platform or industry. In the meantime, if you are looking for general instructions on adding text to digital assets, here are common methods: Microscope Imaging (ImageJ/FIJI) 48 % for pembrolizumab alone)

| Patent | Publication | Claims | |--------|-------------|--------| | (Migdra Therapeutics) | 2023 | Core pyrimidine scaffold, GCN2 binding pocket, specific substitution pattern (isoindolinone). | | US 2024/018923 | 2024 | Method of use in oncology (combination with checkpoint inhibitors). | | US 2025/009874 | 2025 | Biomarker‑guided dosing based on phospho‑eIF2α levels in PBMCs. | | EP 2025/001234 | 2025 | Formulation for enhanced oral bioavailability (solid dispersion). |

| Indication | TAM (2026, $B) | Current Standard of Care | Competitive Edge of MIGD‑061 | |------------|----------------|--------------------------|-------------------------------| | | 45 | PD‑1/PD‑L1 mAbs (pembrolizumab, nivolumab) ± CTLA‑4 | First‑in‑class ISR modulator ; potential to convert “cold” tumours to “hot” via immune‑reprogramming. | | Amyotrophic Lateral Sclerosis (ALS) | 6 | Riluzole, edaravone (limited efficacy) | Oral, disease‑modifying mechanism distinct from excitotoxicity; Orphan designation may accelerate path to market. | | Flavivirus infections (Dengue, Zika) | 1.2 (episodic) | Supportive care | Host‑targeted antiviral with high barrier to resistance. |